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Abstract
Introduction Patients who have undergone mantle radiotherapy
for Hodgkin's disease (HD) are at increased risk of developing
breast cancer. In such patients, breast conserving surgery
(BCS) followed by breast irradiation is generally considered
contraindicated owing to the high cumulative radiation dose.
Mastectomy is therefore recommended as the first option
treatment in these women.
Methods Six patients affected by early breast cancer previously
treated with mantle radiation for HD underwent BCS associated
with full-dose intraoperative radiotherapy with electrons
(ELIOT).
Results A total dose of 21 Gy (prescribed at 90% isodose) in
five cases and 17 Gy (at 100% isodose) in one case were
delivered directly to the mammary gland without acute
complications and with good cosmetic results. After an average
of 30.8 months of follow up, no late sequelae were observed
and the patients are free of disease.
Conclusion In patients previously irradiated for HD, ELIOT can
avoid repeat irradiation of the whole breast, permit BCS and
decrease the number of avoidable mastectomies.
Introduction
The risk of developing breast cancer after radiotherapy for
Hodgkin's disease (HD) is well documented and is attributed
to the incidental inclusion of portions of the breast in the por-
tals used to irradiate the mediastinum with or without infracla-
vicular/axillary regions [1,2]. This increased risk depends on
several patient and treatment factors, including radiation dose,
radiation treatment field and age at treatment [3]. The esti-
mated risk is also affected by the duration of follow up after
radiotherapy and the method used to calculate risk [4]. Based
on concern about possible severe sequelae arising after a high
total cumulative dose to the breast, several authors [5,6] have
suggested mastectomy as the treatment of choice for breast
cancer arising after radiotherapy for HD.
Few studies have been published whereby alternative thera-
pies to mastectomy have been employed; they describe local
excision alone, or interstitial brachytherapy and local excision
followed by local field external beam radiotherapy [7-10].
In order to avoid a dangerously high total cumulative dose of
radiotherapy to the whole breast, soft tissues of the thoracic
wall, lung and heart, without rejecting the possibility of breast
conserving surgery (BCS), we evaluated the potential of per-
forming full-dose intraoperative radiotherapy with electrons
BCS = breast conserving surgery; ELIOT = intraoperative radiotherapy with electrons; EORTC = European Organization for Research and Treatment 
of Cancer; HD = Hodgkin's disease; MeV = mega-electron volts; PBI = partial-breast irradiation;PFR = postoperative fractionated radiotherapy; 
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(ELIOT) in women with early breast cancer who had been pre-
viously irradiated for HD.
Materials and methods
Between July 1999 and April 2005, 756 breast cancer
patients who were candidates for BCS received ELIOT as the
sole radiation treatment in the European Institute of Oncology
in Milan. Of these, 100 patients had been treated in the past
within a preliminary validation phase I study [11,12] and 440
patients are currently in an institutional phase III ongoing rand-
omized clinical trial, in which 21 Gy ELIOT (prescribed at 90%
isodose) is prospectively compared with external postopera-
tive fractionated radiotherapy (PFR) including elective treat-
ment of the whole breast. Eligibility criteria for the ELIOT
randomized trial included patients aged between 48 and 75
years affected by a unicentric breast invasive carcinoma with
a maximum diameter of 2.5 cm. Locally advanced tumors (T3
and T4), the presence of a contralateral synchronous or meta-
chronous tumor, non-invasive carcinomas (including Paget's
disease), other breast malignancies different from carcinoma,
multifocality or multicentricity of the disease, previous surgical
biopsy and previous oncological history are considered exclu-
sion criteria, while a breast thickness superior to 3 cm is con-
sidered a technical contraindication, it being impossible to
deliver energy of more than 9 mega-electron volts (MeV) with
the present ELIOT dedicated linac. No particular tumor breast
locations are excluded from ELIOT, but the close proximity of
the tumor to the skin and pectoral major muscle infiltration are
considered relative contraindication for ELIOT. In fact, in these
cases, the irradiation of the entire breast, including skin and
pectoral major muscle, is mandatory. Finally, if the tumor is very
close to the axilla, ELIOT is avoided due to the risk of irradiat-
ing the axillary nerves and vessels.
In a selected group of 216 invasive breast cancer patients
who were candidates for BCS, and who had specifically asked
for and signed informed consent for ELIOT or in whom PFR
was not considered safe or feasible due to clinical reasons
(e.g. severe cardiopathy, large scars from skin burns, vitiligo,
geographic or social obstacles), ELIOT was performed out-
side the randomized trial. In this selected group of patients,
only the tumor size (larger than 2.5 cm), locally advanced dis-
ease, multifocality or multicentricity were considered exclusion
criteria. Of these 216 patients, 6 were previously treated for
HD and received mantle radiation (Table 1).
The breast cancer presentation of these six patients is
described in Table 2. Five patients underwent BCS and radi-
oguided sentinel lymph node biopsy according to the standard
technique adopted at the European Institute of Oncology [13].
Table 1
Presentation of and therapy for Hodgkin's disease
Patient no. Age (years) Diagnosis Stage Therapy
1 29 HD, MC IIA MOPP × 6, Mantle 36 Gy
2 28 HD, NS IIB MOPP × 4, ABVD × 4, Mantle 20 Gy
3 42 Had IIB ABVD × 3, Mantle 40 Gy
4 38 HD, MC IIA MOPP × 6, Mantle 40 Gy
5 24 HD, NS IIB MOPP × 6, Mantle 40 Gy
6 30 HD, NS IIA MOPP × 4, ABVD × 4, Mantle 36 Gy
aNo histologic subtype determined. ABVD, adriamicine, bleomycin, vinblastine, dacarbazine; HD, Hodgkin's disease; MC, mixed cellularity; MOPP, 
nitrogen mustard, vincristine, procarbazine, prednisone; NS, nodular sclerosis.
Table 2
Presentation of breast cancer
Patient no. Age (years) Interval since radiation for HD (years) ELIOT dose
1 35 16 21 Gy (90% isodose), 7 MeV
2 42 14 17 Gy (100% isodose), 7 MeV
3 50 8 21 Gy (90% isodose), 9 MeV
4 50 12 21 Gy (90% isodose), 9 MeV
5 34 10 21 Gy (90% isodose), 7 MeV
6 39 9 21 Gy (90% isodose), 9 MeV
HD, Hodgkin's disease; MeV, mega electron volts.Available online http://breast-cancer-research.com/content/7/5/R828
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In four out of the five cases, the biopsy showed that the senti-
nel lymph nodes were free of metastasis, so complete axillary
dissection was not performed. In one patient, due to the pres-
ence of clinically metastatic axillary nodes, a complete axillary
dissection was performed directly.
The radio-surgical technique of the six ELIOT procedures did
not differ from the 'classic' technique, which has been
described previously [14] in patients not previously irradiated
for HD.
To evaluate acute and late radiation morbidity, the Radiation
Therapy Oncology Group (RTOG) and European Organiza-
tion for Research and Treatment of Cancer (EORTC) scoring
scheme [15] was applied on the first and seventh day of the
radio-surgical treatment and every six months during follow up.
Radiation therapy device
The dedicated ELIOT machine (Novac7, Hitesys, Italy) is a
miniaturized linear accelerator that can be moved by a robotic
arm, docked in the operating room and fulfils the statutory
requirements with respect to radiological protection. Addi-
tional barriers (from 5 to 15 mm lead) are provided for position-
ing around the operating table. A lead shield (15 cm thick) is
also placed under the surgical bed corresponding to the elec-
tron field (beam stopper). ELIOT delivers a single full-dose of
radiation directly to the tumor bed after removal of the tumor.
Based on the radiobiological models used to predict radiation
effects (linear-quadratic surviving fraction or multitarget surviv-
ing fraction) [16], we can estimate that a dose of 60 Gy deliv-
ered at 2 Gy daily, which is the radiation dose required to
control the microscopical residual disease after breast resec-
tion, is equivalent to a single fraction of 20 to 22 Gy when
using an α/β ratio at 10 Gy, typical for tumors and acute react-
ing tissues. Using the same equation, but calculating the toler-
ance of late responding tissues (α/β ratio at 3 Gy), this
equivalent value increases to at least 110 Gy. The linac does
not produce photons, but only delivers electron beams at four
different energy levels: 3, 5, 7 and 9 MeV as nominal energies,
corresponding to 4.5, 5.2, 6.5 and 7.8 MeV effective energies
to the phantom surface, respectively. The depth of 80% isod-
ose ranged between 13 mm (3 MeV, not used in clinical prac-
tice) and 24 mm (9 MeV).
In one patient, a total dose of 17 Gy (prescribed at 100% isod-
ose) using electron beams (7 MeV energy) was delivered. In
five patients, 21 Gy (prescribed at 90% isodose, 7 or 9 MeV
of energy) were administered.
Results
The biological characteristics of the tumors are shown in Table
3. Two patients received adjuvant chemotherapy with cyclo-
phosphamide-methotrexate/5-fluorouracil, followed by
tamoxifen 20 mg/day for 5 years associated in one case with
LHRH analogue for 2 years. One patient received adriamicin/
cyclophosphamide followed by tamoxifen 20 mg/day for 5
years associated with LHRH analogue for 2 years. Three
patients received tamoxifen 20 mg/day for 5 years, associated
in two cases with LHRH analogue for 2 years.
ELIOT was well tolerated in all patients without any unusual
acute reactions (grade 0 according to the EORTC/RTOG
acute radiation morbidity criteria). In the patients with longer
follow up, no late sequelae were observed (grade 0 according
to the EORTC/RTOG late radiation morbidity scoring scheme)
and all women had an excellent cosmetic result. All the
patients are free of disease after 53, 38, 29, 24, 23 and 17
months of follow up (average 30.8).
Discussion
Previous mantle radiotherapy for HD is considered a contrain-
dication to BCS and radiotherapy [17]. This is based on con-
cerns about possible severe sequelae arising from a high total
cumulative dose, exceeding normal tissue tolerance, being
delivered to the portions of the breast that have presumably
already received radiation for the lymphoma, even though
modifications of the breast gland over time render the exact
calculation of the dose infeasible many years after radiation
delivery. Most authors consider these patients at significant
risk of complications (fibrosis, skin and soft tissue necrosis, rib
Table 3
Characteristics of the breast cancer
Patient no. Tumor site T N G ER, PgR KI67 PVI
1 UO 1c 0 (sn) 2 15%, 25% 11% No
2L I1 c 0  ( s n ) 3 0 % ,  0 % 7 0 % N o
3 C 1c (is) 0 (sn) 1 90%, 90% 13% No
4 S 1c 1a 2 85%, 85% 25% No
5 UO 2 1a 2 30%, 0% 27% Yes
6 UO 1b 0(sn) 1 90%, 90% 8% No
T, tumor size; N, axillary lymph nodes; G, tumor grade; ER, estrogen receptors; PgR, progesterone receptors; KI67, proliferative index; C, central; 
is, extended intraductal component associated; LI, lower inner; PVI, perivascular invasion; S, superior; sn, sentinel node; UO, upper outer.Breast Cancer Research    Vol 7 No 5    Intra et al.
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fractures, potential lung and heart toxicities) [6] and do not
candidate them for BCS and adjuvant radiotherapy. In con-
trast, other reports [18,19] support BCS followed by PFR
when breast cancer develops many years after radiotherapy
for HD. At present, no consensus exists regarding the correct
management of breast cancer after mantle irradiation for HD
and, given the discordant results and the small number of
women treated with BCS, mastectomy continues to be recom-
mended as the standard treatment. To avoid a high total cumu-
lative dose to portions of the breast or soft tissues of the
thoracic wall, one of the conservative options is to treat just the
tumor bed: the irradiation of a small volume of the breast and
adjacent structures could allow the risk of complications to be
minimized [7-10]. Therefore, over the past decade there has
been increasing interest in a variety of radiation techniques
designed to treat only the portion of the breast deemed to be
at high risk for local recurrence [20]: these include brachyther-
apy implants, MammoSite applicator, intraoperative orthovolt-
age device, and 3D conformal or intensity-modulated external
radiotherapy (partial-breast irradiation (PBI)). All these tech-
niques have similar indications but different applications
[21,22]. In particular, they differ in the source of radiation (for
example, X-ray, Iridium, photons) and the amount of breast vol-
ume treated. Although 5 to 7 year outcome data on patients
treated with PBI are now becoming available, many issues
remain unresolved, including the clinical and pathological
selection criteria of patients, radiation dose and fractionation,
and how these relate to the standard fractionation for whole
breast irradiation, appropriate target volume, local control
within the untreated ipsilateral breast tissue, and overall sur-
vival. With a view to furnishing guidelines and clarifying the
issues of major controversy, a workshop on PBI was held in
Bethesda, in December 2002. The workshop report empha-
sized the importance of education and training with regard to
the results of PBI as it becomes an emerging clinical treatment
[23]. In particular, ELIOT, a new radiotherapeutic technique
that delivers a single dose of radiation directly to the tumor bed
during the conservative surgical treatment of early breast can-
cer, has been proposed for evaluation in randomized clinical
trials as a possible alternative to standard PFR.
When in July 1999 we focused our interest on the use of intra-
operative radiotherapy as an exclusive treatment in small uni-
focal infiltrating breast carcinomas, we considered that ELIOT
could be specifically applied in all those situations in which
PFR was not considered safe or feasible for various reasons
(for example, severe cardiopathy, large hypertrophic scarring
from skin burns, vitiligo, geographic or social obstacles) [24]
and, in particular, in patients irradiated for HD. After our first
preliminary report [25], ELIOT was proposed in six patients
previously irradiated for HD. In all cases, the dose delivered
and the energy of electron beams from ELIOT did not differ
from those in the other 549 patients submitted to ELIOT; in
one patient a total dose of 17 Gy (prescribed at 100% isod-
ose) using electron beams at 7 MeV energy and in five patients
doses of 21 Gy (90% isodose, 7 and 9 MeV of energy) were
delivered. The different electron energies administrated (7 or
9 MeV) are related to the different breast gland thickness.
The radio-surgical technique of the six ELIOT procedures did
not differ from the 'classic' technique used for previously non-
irradiated patients [14]. In particular, to ensure a good cover-
age of the target by the radiation dose and maximal protection
of the normal tissues in the operative area, adequate prepara-
tion for irradiation of the portion of breast gland to undergo
ELIOT is necessary. Protective devices are placed between
the gland and the pectoral muscle; a dedicated lead disk 5 mm
thick and an aluminium disk 4 mm thick, available in various
diameters (4, 5, 6, 8, 10 cm) are commonly used. The wall pro-
tection is guaranteed both by the absorption properties of the
lead and aluminium and the 9 mm outdistance created by the
disks.
We scored the radiation morbidity according to the RTOG/
EORTC criteria [15]. ELIOT was well tolerated without any
unusual acute reactions despite previous breast irradiation.
We did not observe any ischemic or necrotic problems of the
skin flap due to the careful sparing of the subcutaneous ves-
sels during the mobilization of the residual breast around the
tumor bed. No increased post-operative complications (pain,
seroma, emathoma, infection) were observed in these six
patients when compared to the overall group of ELIOT
patients. The length of hospital stay was therefore not pro-
longed. The cosmetic outcome was also very good in all
patients: no skin erythema was observed as a result of the
complete removal of the skin from the radiation beam.
The follow up is too short (average 30.8 months) to evaluate
late sequelae in these six re-irradiated patients but no compli-
cations were observed in the four patients with more than 2
years of follow up.
Conclusion
ELIOT dramatically reduces the radiation exposure of the nor-
mal tissues and, in particular, of the previously irradiated
breast, avoiding a high total cumulative dose to the gland and
to the soft tissues of the thoracic wall. In patients previously
treated for HD, ELIOT permits BCS independently of the inter-
val between mantle radiotherapy and breast surgery, without
acute local complications, decreasing the number of avoidable
mastectomies. A longer follow up is necessary to evaluate the
incidence of radiation-induced sequelae and the local recur-
rence rate.
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